Gilead Sciences, Inc. (GILD): Gilead Sciences +3% AH on strong leukemia drug …Seeking Alpha… not fit for chemotherapy will be stopped early based on an analysis showing highly statistically significant efficacy for the primary endpoint of progressi…
Promising Durability Data Presented for BioVentrix‚Äôs Novel Heart Failure … – PharmiWeb.com (press release)
|
Promising Durability Data Presented for BioVentrix‚Äôs Novel Heart Failure …
PharmiWeb.com (press release) BioVentrix a pioneer of technologies and procedures for less-invasive treatment of heart failure (HF) today announced the presentation of scientific data demonstrating the durability of its Revivent‚Ñ¢ Myocardial Anchoring System in 24 patients one … |
Health Officials Ask Stores To Yank Fat-Burning Supplement Linked To Liver … – The Consumerist
WFAA |
Health Officials Ask Stores To Yank Fat-Burning Supplement Linked To Liver …
The Consumerist Hawaii health officials are asking stores to stop selling the fat-burning supplment OxyElite Pro after an investigation linked it to cases of liver failure and acute hepatitis in 29 people. Two of those people had to undergo liver transplants and one … Weight-Loss Supplement Tied to Liver Failure CasesWebMD ‘Fat-burning’ supplement linked to liver failureWBIR-TV Diet supplement linked to liver failure ordered off Hawaii shelvesHawaii News Now KVUE –New York Daily News –wtkr.com all 68 news articles » |
Organ donor promotion at DMV brings increase in registrations – Science Codex
Science CodexOrgan donor promotion at DMV brings increase in registrationsScience CodexOrgan donor promotion at DMV brings increase in registrations. More than 90 percent of the public supports organ donation, yet less than half the population register…
As 16-year-old Lorissa Green lay dying, her grieving mother started a letter … – Pacific Northwest Inlander
Pacific Northwest Inlander |
As 16-year-old Lorissa Green lay dying, her grieving mother started a letter …
Pacific Northwest Inlander Her spleen and colon were ruptured, her left lung collapsed. Brain death worsened her condition, cutting off her body’s ability to regulate blood and oxygen flow to her organs and leaving her condition unstable. So LifeCenter’s medical personnel were … |
UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic … – Benzinga
UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic …BenzingaThis DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free su…
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia … – Wall Street Journal
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia …Wall Street JournalThis DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progres…
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia … – MarketWatch
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia …MarketWatchThis DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-fre…
UW researchers aim to cure mysterious 'chemo brain' condition – KOMO News
KOMO News |
UW researchers aim to cure mysterious ‘chemo brain’ condition
KOMO News UW researchers aim to cure mysterious ‘chemo brain’ condition. Constance Claussen has experienced cognitive difficulties since going through chemotherapy and a stem cell transplant for multiple myeloma. (Courtesy Constance Claussen.) SEATTLE — Pam … |
U of S labs look at producing cancer fighting antibodies – News Talk 980 CJME
|
U of S labs look at producing cancer fighting antibodies
News Talk 980 CJME An investment of $1.7 million from the federal government’s Western Economic Diversification (WED) and the provincial government helped the lab buy the necessary infrastructure and tools to create the antibodies at a much larger rate. “Anytime we can … |